Clint Coghill’s Coghill Capital Management filed SEC 13G earlier today and revealed 9,065,360 shares in General Moly, Inc. (GMO), corresponding to a 9.98% passive stake. Coghill Capital Management does make change to its position after the second quarter. GMO has lost 50% so far this year. The stock is now pricing at $3.43.
According to Insider Monkey’s hedge fund tracking list, eight hedge funds invested in GMO in the third quarter. Beside Coghill Capital Management’s largest chunk, Stuart Peterson’s Artis Capital Management increased its position by 42% and reported 1.84 million shares at the end of September. Phil Falcone’s Harbinger had 1.40 million shares in GMO. Steven Cohen’s SAC Capital Advisors and David. E. Shaw’s D. E. Shaw sold out their GMO positions during the third quarter.
Coghill Capital Management is a Chicago-based hedge fund. The firm specializes in small cap value equity management. According to Linkedin, the firm provides services for Endowments, Foundations, Family Offices, High Net Worth Individuals, Pension Plans and Institutional Investors. The firm reported a $96 million 13F portfolio at the end of the third quarter. It mainly invests in Basic Materials and Technology sector.
According to Google Finance, General Moly, Inc. “is a development-stage company in the business of the exploration, development and mining of properties primarily containing molybdenum. The Company’s primary asset is 80% interest in the Mt. Hope Project (Mt. Hope Project), a primary molybdenum property, located in Eureka County, Nevada. As of December 31, 2009, the Mt. Hope Project had contained proven and probable molybdenum reserves totaling 1.3 billion pounds of which 1.1 billion pounds are estimated to be recoverable. In addition, it owns other non-core properties and mineral rights.”